Stereotactic Ablative Radiotherapie of Bone Metastases in an Oligogemetastaseerd Setting: One-Year Follow-Up of the BONY-M Fase 2-Trial

SABR is increasingly applied to treat oligometastatic disease (OMD). As patients may be asymptomatic, severe toxicity must be carefully balanced with effect in this setting. The BONY-M trial aimed to determine the efficacy and toxicity after SABR of uncomplicated bone metastases in patients with OMD.